Over-expression of miR-124 impairs proliferation, invasion and epithelial-mesenchymal transition in pituitary prolactinoma by targeting PHD finger protein 19

Zongxi Li1, Lingxuan Ren2, Shoujie Wang3*
1Department of Neurosurgery, Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College, Chengdu City, Sichuan Province 610500, 2Department of Child Healthcare, Cheng Du Xin Du Maternal & Child Health Care Hospital, Chengdu City, Sichuan Province 610500, 3Department of Neurosurgery, The Second Affiliated Hospital of Air Force Military Medical University, Xi’an City, Shaanxi Province 710038, China

*For correspondence: Email: sjwang2366@163.com; Tel: +86-029-84717846

Abstract

Purpose: To determine the effect of miR-124 in pituitary prolactinoma.
Methods: The viability and proliferation of prolactinoma cells were investigated using Cell Counting Kit-8 and 5-ethynyl-2'-deoxyuridine staining assays. Cell migration and invasion were investigated using the transwell assay. The epithelial-mesenchymal transition was investigated using western blotting. The target gene of miR-124 was verified by the luciferase activity assay.
Results: The viability and proliferation of prolactinoma cells were repressed by miR-124 over-expression (p < 0.01). Forced miR-124 expression suppressed prolactinoma cell migration and invasion (p < 0.01). E-cadherin expression was enhanced, while N-cadherin and vimentin were reduced, by miR-124 over-expression (p < 0.01). PHF19 (plant homeodomain-like finger protein 19) contains an miR-124 binding site, and PHF19 over-expression enhanced cell proliferation, promoted cell migration and invasion, reduced E-cadherin expression and enhanced N-cadherin and vimentin expression in prolactinoma cells. Additionally, miR-124 mimic-induced suppression of prolactinoma cell growth and metastasis was attenuated by forced PHF19 expression.
Conclusion: MiR-124 retards prolactinoma cell growth and metastasis by reducing PHF19, providing a promising therapeutic target for prolactinoma.

Keywords: miR-124, PHF19, Pituitary prolactinoma, Cell proliferation, Cell invasion, Cell migration
MicroRNAs (miRNAs) are potential biomarkers for pituitary tumors [4]. The regulatory role of miRNAs in prolactinoma progression has been widely investigated. A previous study showed that miR-124 is a tumor suppressor in bladder cancer [5], and miR-124 suppressed glioblastoma multiforme cell proliferation [6]. However, the effect of miR-124 on prolactinoma has not yet been reported. Plant homeodomain-like finger protein 19 (PHF19, also called PCL3) is a homolog of polycomb-like proteins that participates in the cell cycle and development through epigenetic regulation of homeotic genes [7]. Additionally, PHF19 has been implicated in miR-124a-mediated glioma cell proliferation [8]. Therefore, we hypothesized that miR-124 might suppress prolactinoma cell growth and metastasis by down-regulating PHF19.

EXPERIMENTAL

Cell culture and transfection

Rat MMQ and GH3 cells were cultured in F-12K culture medium (Beyotime Institute of Biotechnology, Haimen, China) containing 10% horse serum and 5% fetal bovine serum (Beyotime Institute of Biotechnology) in a 37 °C incubator. MiR-124 mimic and inhibitor were synthesized by Invitrogen (Carlsbad, CA, USA). Cells (3 × 10⁵ cells/well) were transfected with 20 nM of miR-124 mimic or inhibitor or 300 nM pcDNA-PHF19 (Invitrogen) using Lipofectamine 2000 (Invitrogen).

Cell viability and proliferation

Cells with the indicated transfection were seeded in 96-well plates for 24, 48, or 72 h. Cell Counting Kit-8 solution (Sigma Aldrich, St. Louis, MO, USA) was added and incubated for another 2 h. Next, the optical density at 490 nm was measured. To evaluate cell proliferation, cells were seeded in 96-well plates for 24 h and then incubated with medium containing 100 μL of 5-ethyl-2′-deoxyuridine EdU (50 μM; Invitrogen) for 12 h. Following fixation in 4% paraformaldehyde, the cells were permeabilized and then incubated with Apollo® 488 fluorescent staining solution (Beyotime Institute of Biotechnology). The nuclei were stained with 4’,6-diamidino-2-phenylindole, and the cells were then observed under a fluorescence microscope (Nikon, Tokyo, Japan).

Cell migration and invasion

Cells with the indicated transfection were seeded in Matrigel-precoated (BD Biosciences, Bedford, MA, USA) chambers (Corning, Tewksbury, MA, USA) for 48 h. The paraformaldehyde-fixed and crystal violet-stained invasive cells were imaged under a microscope (Olympus). For cell migration, the cells were seeded in the chamber without Matrigel precoating.

Luciferase reporter assay

Wild-type or mutant sequences of the 3′ untranslated region (3′ UTR) of PHF19 were subcloned into pmiR-RB-REPORT (Riobio, Guangzhou, China) and were called PHF19 3’UTR WT or PHF19 3’UTR MUT, respectively. The vectors were cotransfected with miR-124 mimic or inhibitor into HEK-293T cells, and the Dual-Luciferase Reporter Assay System (Promega, Madison, Wisconsin, USA) was used to determine the luciferase activity.

Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)

MiRNAs were extracted from cells, and the miRNAs were then reverse transcribed into cDNAs. Analysis of miR-124 expression was performed using SYBR Green Master Mix (Roche, Mannheim, Germany) relative to U6. The primer sequences are shown in Table 1.

<table>
<thead>
<tr>
<th>ID</th>
<th>Sequence (5′-3′)</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-124 Forward</td>
<td>TGACTTCAACAGCGACACCACC</td>
</tr>
<tr>
<td>miR-124 Reverse</td>
<td>CACCATGTTGCTGTAGCCAAAA</td>
</tr>
<tr>
<td>U6 Forward</td>
<td>CTGCGTTGCGGACAGCAACA</td>
</tr>
<tr>
<td>U6 Reverse</td>
<td>AACGCTTCACGAATTTGCCTG</td>
</tr>
</tbody>
</table>

Western blotting

MMQ and GH3 cell lysates were separated using electrophoresis, followed by transfer to polyvinylidene difluoride membranes. The membranes were incubated with primary antibodies against PHF19, E-cadherin, N-cadherin, vimentin, and β-actin (Cell Signaling Technology, Danvers, MA, USA). Horseradish peroxidase-linked secondary antibody (Cell Signaling Technology) was used to incubate the membranes, and an enhanced chemiluminescence detection kit (Pierce; Thermo Fisher Scientific) was used to analyze the immunoreactivities of bands in the membranes.

Statistical analysis

The data are presented as means ± standard error of the mean. Student’s t-test or one-way
analysis of variance was used to analyze the difference between groups. \( P < 0.05 \) was considered significant.

RESULTS

Forced miR-124 represses the cell proliferation of pituitary prolactinoma

qRT-PCR analysis showed higher expression of miR-124 by miR-124 mimic than NC mimic and mock (Figure 1 A). Functional assays indicated that ectopic expression of miR-124 reduced the viability of MMQ and GH3 cells (Figure 1 B). Additionally, EdU-positive MMQ and GH3 cells transfected with miR-124 mimic were lower than those transfected with NC mimic (Figure 1 C), suggesting that forced miR-124 repressed pituitary prolactinoma cell proliferation.

Figure 1: Forced miR-124 expression represses the cell proliferation of pituitary prolactinoma. (A) Higher miR-124 expression in cells transfected with miR-124 mimic than with NC mimic and mock. (B) miR-124 over-expression decreased the viability of MMQ and GH3 cells. (C) miR-124 over-expression decreased the number of EdU-positive MMQ and GH3 cells; * \( p < 0.05 \), ** \( p < 0.01 \), *** \( p < 0.001 \)

Forced miR-124 represses the cell migration and invasion of pituitary prolactinoma

The transwell assay showed the suppressive effect of miR-124 on prolactinoma cell migration (Figure 2A) and invasion (Figure 2B). Additionally, miR-124 over-expression increased the E-cadherin protein expression and reduced N-cadherin and vimentin protein expression (Figure 2C), indicating the anti-invasive role of miR-124 in pituitary prolactinoma.

Figure 2: Forced miR-124 represses the cell migration and invasion of pituitary prolactinoma. (A) miR-124 over-expression decreased MMQ and GH3 cell migration. (B) miR-124 over-expression decreased MMQ and GH3 cell invasion. (C) miR-124 over-expression increased E-cadherin and decreased N-cadherin and vimentin expression in MMQ and GH3 cells; ** \( p < 0.01 \), *** \( p < 0.001 \)

MiR-124 binds to PHF19

Bioinformatics analysis (TargetScan: http://www.targetscan.org/vert_72/) demonstrated that miR-124 binds to the 3′UTR of PHF19 (Figure 3A). miR-124 over-expression reduced the luciferase activity of PHF19 3′UTR WT (Figure 3B), while miR-124 inhibition enhanced its luciferase activity (Figure 3B). However, the activity of PHF19 3′UTR MUT was not affected by either miR-124 mimic or inhibitor (Figure 3B). Additionally, the suppressive effect of miR-124 on PHF19 expression and promotive effect of miR-124 silencing on PHF19 expression in MMQ and GH3 cells (Figure 3C) suggest that miR-124 directly binds to PHF19 in pituitary prolactinoma.

Forced PHF19 attenuates the suppressive effect of miR-124 on pituitary prolactinoma progression

Western blot analysis showed higher protein expression of PHF19 by transfection with
pcDNA-PHF19 than with the empty vector (Figure 4 A). PHF19 over-expression increased MMQ cell viability (Figure 4 B), enhanced the number of EdU-positive cells (Figure 4 C), and promoted cell migration (Figure 4 D) and invasion (Figure 4 E). Additionally, E-cadherin protein expression was reduced in MMQ transfected with pcDNA-PHF19, while N-cadherin and vimentin protein expression was enhanced (Figure 4 F). Cotransfection with miR-124 mimic and pcDNA-PHF19 attenuated the suppressive effects of miR-124 on pituitary prolactinoma cell viability (Figure 4 B), proliferation (Figure 4 C), migration (Figure 4 D), and invasion (Figure 4 E). Additionally, enhanced E-cadherin and reduced N-cadherin and vimentin expression in MMQ transfected with miR-124 was also reversed by cotransfection with miR-124 mimic and pcDNA-PHF19 (Figure 4 F). These results suggest that miR-124 retarded pituitary prolactinoma progression by negative regulating PHF19.

DISCUSSION

Dysregulated miRNA expression is a hallmark of pituitary prolactinoma, and miRNAs function as either oncogenes or tumor suppressors in pituitary prolactinoma [4]. Considering the tumor-repressive effect of miR-124 on various tumors, the detailed mechanism of miR-124 on pituitary prolactinoma progression was evaluated in this study.

Circulating miRNAs are considered diagnostic or prognostic biomarkers in pituitary tumors [9]. Because miR-124 is a potential diagnostic biomarker in colorectal cancer [10], the clinical relationship between miR-124 and prolactinoma patients should be investigated to validate the diagnostic or prognostic role of miR-124 in prolactinoma. Functional assays have indicated

Figure 3: MiR-124 binds to PHF19. (A) Potential binding site of miR-124 on PHF19 from bioinformatics analysis using TargetScan (http://www.targetscan.org/vert_72/). (B) Transfection with miR-124 mimic decreased the luciferase activity of PHF19 3'UTR WT, while transfection with miR-124 inhibitor increased the luciferase activity of PHF19 3'UTR WT. The activity of PHF19 3'UTR MUT was not affected by either miR-124 mimic or inhibitor. (C) miR-124 over-expression decreased PHF19, while miR-124 inhibition increased PHF19 in MMQ and GH3 cells; **p < 0.01. ***p < 0.001

Figure 4: Forced PHF19 expression attenuates the suppressive effect of miR-124 on pituitary prolactinoma progression. (A) Higher PHF19 protein expression following transfection with pcDNA-PHF19 than with empty vector over-expression. (B) PHF19 increased MMQ cell viability and attenuated miR-124-induced decrease in MMQ cell viability. (C) PHF19 over-expression increased MMQ cell proliferation and attenuated the miR-124-induced decrease in MMQ cell proliferation. (D) PHF19 over-expression increased MMQ cell migration and attenuated the miR-124-induced decrease in MMQ cell migration. (E) PHF19 over-expression increased MMQ cell invasion and attenuated the miR-124-induced decrease in MMQ cell invasion. (F) PHF19 over-expression reduced E-cadherin and enhanced N-cadherin and vimentin expression in MMQ cells and attenuated miR-124-induced enhancement of E-cadherin and reduction of N-cadherin and vimentin expression in MMQ cells; *#p < 0.05, **, ###p < 0.01, ***p < 0.001
the tumor-suppressive role of miR-124 on prolactinoma. The epithelial-mesenchymal transition confers metastatic properties on tumor cells and is implicated in carcinogenesis through resistance to apoptotic stimuli and enhanced mobility and invasion [11]. MicroRNA-124 suppresses the metastatic properties of prolactinoma with enhanced E-cadherin and reduced N-cadherin and vimentin expression. Therefore, miR-124 may be a therapeutic target of prolactinoma.

Multiple PHFs promote tumorigenesis through epigenetic regulation of target genes [12-14]. The Tudor domain of PHF19 binds to histone H3K36me3 [15], enhancing H3K27me3 deposition to promote the tumorigenicity of multiple myeloma [16]. PHF19 inhibition is involved in the anti-oncogenic role of miR-195-5p in hepatocellular carcinoma progression [17]. We showed that miR-124 binds to the 3'UTR of PHF19, and the silencing of miR-124 promotes PHF19 expression in prolactinoma cells. Further functional assays demonstrated that PHF19 promotes the tumorigenesis of prolactinoma through enhanced cell viability, proliferation, migration, invasion and EMT. PHF19 suppression by miR-124a retards glioma cell proliferation [8]. This study showed that forced PHF19 attenuates the suppressive effect of miR-124 on pituitary prolactinoma progression. Therefore, miR-124 retards pituitary prolactinoma progression by negatively regulating PHF19.

miR-124 methylation is a biomarker of cervical cancer [18], and methylation-modulated silencing of miR-124 facilitates pancreatic cancer metastasis and progression [19]. Deoxyribonucleic acid methylation in the promoter of miR-124 promotes Tat-mediated activation of microglia [20]. Therefore, whether PHF19 epigenetically regulates miR-124 methylation to promote prolactinoma progression requires further investigation. JAK-STAT signaling is implicated in PHF19-mediated multiple myeloma tumorigenicity [16]. The downstream target pathway involved in miR-124/PHF19 axis-modulated prolactinoma progression should also be validated in further studies.

CONCLUSION

The current work characterized the tumor-suppressive role of miR-124 as well as the oncogenic role of PHF19 in prolactinoma progression. MicroRNA-124/PHF19 axis may yield a promising approach to suppress prolactinoma progression.

DECLARATIONS

Acknowledgement

Thanks are due to Mr. Amjad Farooq for his technical assistance, and BioMES, Alpha Genomics Private Limited, Islamabad - Pakistan for editing and reviewing the manuscript. Thanks are also due to the patients who participated in the study.

Conflict of interest

No conflict of interest is associated with this work.

Availability of data and materials

All the data generated or analyzed during this study are included in this published article.

Contribution of authors

We declare that this work was performed by the authors named in this article and that all liabilities pertaining to claims relating to the content of this article will be borne by the authors. Zongxi Li and Shoujie Wang designed the study and supervised the data collection. Lingxuan Ren analyzed and interpreted the data. Zongxi Li, Lingxuan Ren, and Shoujie Wang prepared the manuscript for publication and reviewed the draft of the manuscript. All the authors have read and approved the manuscript.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/rea), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES


